Annual report pursuant to Section 13 and 15(d)

Organization and Description of Business (Narrative) (Details)

v3.23.1
Organization and Description of Business (Narrative) (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 06, 2021
USD ($)
Oct. 05, 2021
Dec. 31, 2022
company
$ / shares
Oct. 31, 2022
$ / shares
Dec. 31, 2021
$ / shares
Number of partner companies that are publicly traded | company     4    
Common Stock, par value | $ / shares     $ 0.001 $ 0.001 $ 0.001
Number of partner companies that have consummated strategic partnerships with industry leaders | company     3    
Maximum          
Bid price of common stock | $ / shares       $ 1.00  
Caelum | AstraZeneca [Member]          
Deconsolidation of consolidated partner company, percentage deconsolidated 100.00% 100.00%      
Deconsolidation of consolidated partner company, upfront payment | $ $ 150        
Caelum | AstraZeneca [Member] | Maximum          
Deconsolidation of consolidated partner company, contingent payment | $ $ 350